Two new clinical papers provide evidence for on-demand and prophylactic use of potential HAE treatment, deucrictibant
New data on a potential HAE treatment, called deucrictibant, was presented at a recent conference, called the Consortium of Independent Immunology Clinics (CIIC) Spring 2026 Conference 17-19 April 2026.
The data, which evaluates safety signals from existing studies, supports the use of both extended-release tablets of deucrictibant for prevention of HAE attacks, and deucrictibant immediate release capsules in the event of a breakthrough attack while on prophylaxis.
Dr Peng Lu, Chief Medical Officer of Pharvaris, said: “These safety data, combined with the post-hoc efficacy analyses of mechanism-on-mechanism treatment of breakthrough attacks, provide evidence for the potential of the combined use of deucrictibant as a prophylactic treatment and as an on-demand medication. Bradykinin-mediated angioedema can be prevented by administering a bradykinin B2 receptor antagonist that exceeds the therapeutic threshold to compete with bradykinin. If the plasma concentration of drug drops below this threshold, a person may be susceptible to a breakthrough attack; rapid exposure to an on-demand treatment using the same mechanism could be a compelling treatment approach in this scenario. We look forward to further exploring this strategy.”
Additionally, in an earlier announcement, the company shared a business update as part of its Q3 2026 financial reporting. In it, they indicated:
- Enrollment is complete for a pivotal study of deucrictibant as a long-term prophylaxis to prevent HAE attacks
- Pharvaris expects to submit deucrictibant to the US regulatory authorities in the first half of 2026
- Enrollment in a study examining the use of deucrictibant to treat and prevent acquired angioedema attacks caused by C1 inhibitor deficiency is ongoing
(Source: Pharvaris)